Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study

by Miljenko V. Pilepich, Kathryn Winter, Colleen A. Lawton, Robert E. Krisch, Harvey B. Wolkov, Benjamin Movsas, Eugen B. Hug, Sucha O. Asbell, David Grignon
Published 2020-02-01

The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.

by Larissa J Lee, Elena Ratner, Mohamed Uduman, Kathryn Winter, Marta Boeke, Kathryn M Greven, Stephanie King, Thomas W Burke, Kelly Underhill, Harold Kim, Raleigh J Boulware, Herbert Yu, Vinita Parkash, Lingeng Lu, David Gaffney, Adam P Dicker, Joanne Weidhaas
Published 2014-01-01

Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704

by William F. Regine, MD, Kathryn Winter, MS, Ross A. Abrams, MD, Howard Safran, MD, Ivan L. Kessel, MD, Yuhchyau Chen, MD, PhD, James A. Fugazzi, MD, Eric D. Donnelly, MD, Thomas A. DiPetrillo, MD, Samir Narayan, MD, John P. Plastaras, MD, Rakesh Gaur, MD, Guila Delouya, MD, John H. Suh, MD, Joshua E. Meyer, MD, Michael G. Haddock, MD, Mukund S. Didolkar, MD, Gilbert D.A. Padula, MD, David Johnson, MD, John P. Hoffman, MD, Christopher H. Crane, MD
Published 2018-04-01